TransCode Therapeutics has created a platform of RNA drug candidates with the objective of improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually.
Currently we are continuing research on a variety of both diagnostic and therapeutic approaches targeting biomarkers broadly prevalent across numerous tumor types.
Additionally, TransCode’s other drug candidates, TTX-siPDL1, 64Cu-TTX-MC138, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR and TTX-mRNA, focus on treating cancer using RNA technology made possible through our proprietary delivery platform.
Learn more about how TransCode is advancing new RNA therapies through a modular design engine.